Catalyst Pharmaceuticals (NASDAQ:CPRX) Rating Lowered to “Buy” at StockNews.com

Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

CPRX has been the subject of a number of other reports. Truist Financial lifted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Stephens began coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Trading Up 0.1 %

Shares of CPRX opened at $21.62 on Tuesday. The stock has a market cap of $2.58 billion, a PE ratio of 18.32, a PEG ratio of 3.35 and a beta of 0.75. Catalyst Pharmaceuticals has a 1 year low of $13.12 and a 1 year high of $24.27. The stock has a 50 day simple moving average of $21.80 and a 200-day simple moving average of $19.46.

Insiders Place Their Bets

In related news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 79,500 shares of company stock valued at $1,754,140. Insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $50,000. Larson Financial Group LLC increased its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Catalyst Pharmaceuticals in the second quarter worth $70,000. Finally, Quantbot Technologies LP bought a new position in Catalyst Pharmaceuticals during the third quarter worth about $151,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.